HC Wainwright Reiterates “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They currently have a $16.00 price objective on the biopharmaceutical company’s stock.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Esperion Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $9.33.

Esperion Therapeutics Stock Up 2.5 %

Shares of Esperion Therapeutics stock opened at $2.09 on Wednesday. Esperion Therapeutics has a 52 week low of $0.70 and a 52 week high of $3.40. The stock’s 50-day simple moving average is $2.30 and its 200-day simple moving average is $2.07. The company has a market capitalization of $395.85 million, a price-to-earnings ratio of -0.99 and a beta of 0.89.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.03. The business had revenue of $32.25 million during the quarter, compared to the consensus estimate of $26.84 million. During the same quarter in the previous year, the company earned ($0.76) earnings per share. On average, equities analysts expect that Esperion Therapeutics will post -0.68 earnings per share for the current year.

Hedge Funds Weigh In On Esperion Therapeutics

Several institutional investors have recently made changes to their positions in the company. Spire Wealth Management grew its holdings in Esperion Therapeutics by 69.2% during the 4th quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 7,267 shares in the last quarter. Private Portfolio Partners LLC bought a new position in shares of Esperion Therapeutics during the fourth quarter valued at approximately $30,000. Herbst Group LLC purchased a new position in Esperion Therapeutics during the first quarter valued at approximately $28,000. Summit Financial LLC raised its stake in Esperion Therapeutics by 66.8% in the first quarter. Summit Financial LLC now owns 25,864 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 10,355 shares in the last quarter. Finally, PSI Advisors LLC raised its stake in Esperion Therapeutics by 161.5% in the fourth quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 10,500 shares in the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.